Tumor DNA vaccine taking mucin 1 and survivin as targets and viral vector vaccine

Abstract

The invention discloses a tumor deoxyribonucleic acid (DNA) vaccine taking mucin 1 and survivin as targets and a viral vector vaccine. The invention relates to the field of tumor DNA vaccines and viral vector vaccines, in particular to recombinant DNA vector VR-S8 and VR-MS, recombinant adenovirus Ad-S8 and Ad-MS, and recombinant poxvirus MVA-MS vaccines, and application of the optimum combination of immune ways between DNA vaccines and viral vector vaccines and between the viral vector vaccines in preparing antitumor vaccines.

Description

technical field [0001] The invention relates to the field of tumor DNA vaccine and virus vector vaccine. Specifically, the present invention relates to recombinant DNA vector VR-S8 and VR-MS, recombinant adenovirus Ad-S8 and Ad-MS and recombinant poxvirus MVA-MS vaccine, and DNA vaccine and viral vector vaccine and viral vector vaccine The application of the optimized combination of immunization methods in the preparation of anti-tumor vaccines. Background technique [0002] Survivin is a member of the inhibitor of apoptosis protein (IAP) family, has dual functions of anti-apoptosis and regulation of cell division, and is widely expressed in various embryonic tissues and cancer cells, but not in normal terminally differentiated cells . These characteristics make survivin a new target in the fields of tumorigenesis, development and therapy. [0003] Current research shows that survivin has potential value in tumor gene therapy: its tumor-specific expression is positively c...

AI Technical Summary

Problems solved by technology

From the discovery of MUC1 to the present, a lot of vaccine research work has been carried out with it, and some vaccines have entered the stage of human clinical research, but most of them are traditional polypeptide, protein or dendritic cell (DC) vaccines, Most of these vaccines have problems such as poor immunogenicity or difficulty in preparation; the genetic vaccines that have entered the clinic are mainly recombinant poxvirus vaccines. Although no toxicity has been detected, there are still relatively large safety hazards in primary vaccination-boosting of recombinant poxvirus vaccines directly. , and the clinical effect is not very satisfactory; DNA carrier vaccine is still basically in the preclinical research stage due to its weak immunogenicity

[0007] The previous studies of the inventors of the present invention have shown that increasing the number of VNTRs can enhance the immune effect of MUC1 to a certain extent (see Zhang S et al., 2008). For example, the immune response caused by 33 copies of the MUC1 VNTR tandem repeat sequence is significantly stronger than that of The immune response caused by the tandem repeat sequence of 2 copies of MUC1 VNTR, so the present invention selects the tandem repeat sequence MUC1 VNTR containing 33 as the antigen to design the vaccine, and fuses it with S8 to construct the fusion expression vaccine to enhance the immunity of the vaccine Broad-spectrum and effectiveness, the combination of survivin and MUC1 VNTR for tumor treatment has not been reported

Images